The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
GBI Research, the leading business intelligence provider, has released its latest research “The Future of Metabolic Disorder Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis.” The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global metabolic disorder therapeutics market. The report analyzes the markets for metabolic disorder therapeutics in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, price and volume are forecast until 2015 for the key geographies as well as the leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.
The Global Metabolic Disorders Therapeutics Market is Attractive Despite Poor Safety Profiles of Products
GBI Research finds that the global metabolic therapeutics market is attractive despite product failures.
Metabolic Disorders Therapeutics Market, Global, Drivers and Restraints, 2008
Source: GBI Research
The major factor driving the growth of the market is the rising incidence of obesity and diabetes diseased population in key markets such as the US, the UK and Germany. The global diabetes diseased population in 2008 was 52.4 million and the obesity diseased population was 108.9 million. In 2008, the diabetes market accounted for 95% of the global metabolic disorders therapeutics market. The reason for the significant market share of diabetes drugs is the failure of anti-obesity drugs in proving their efficacy and safety. Acomplia, an anti-obesity drug, was not approved in the US due to poor safety profile and was pulled out of the European market in October 2008. The other existing drugs for obesity are also associated with severe side effects resulting in poor utilization by obesity patients. Product failures related to poor safety profiles have also impacted the diabetes market. Avandia (rosiglitazone) which is a drug for type 2 diabetes is can increase the risk of heart problems. Following the reports of heart related side-effects, the sales of Avandia declined substantially. However, the diabetes market is experiencing overall growth due to the increased utilization of other drugs such as insulin analogues and biguanides.
GBI Research forecasts that the metabolic disorders therapeutics market will grow at a CAGR of 7.2% between 2008 and 2015. The market will be primarily driven by the rising prevalence rates and the market entry of new products such as teplizumab and contrave.
The Global Metabolic Disorders Therapeutics Market is Concentrated with the Top Four Companies Accounting for 60% Market Share
GBI Research finds that global metabolic therapeutics market is a concentrated market with the top four companies accounting for 60% of the market share. The market is dominated by players in the diabetes market. The top six players in the diabetes market accounted for 73% of the diabetes market while the top three players in the obesity market accounted for 63% of the obesity market. Novo Nordisk, Sanofi-aventis, Takeda and Eli Lilly are the leading players in the diabetes market. Roche and Abbott Laboratories lead the obesity market. The competitive landscape in both the markets is set to change due to the success of recent launches and the potential success of new drugs that will be launched during the period 2008-2015. The market will be impacted by the decline in sales of leading products such as GSK’s Avandia, Takeda’s Actos and Abbott’s Meridia. GBI Research estimates that the market share of Eli Lilly and Merck in the diabetes market will increase due to the potential success of teplizumab and Januvia. Teplizumab is in phase III stage and Januvia was launched in 2006 and its sales have increased substantially since launch. The competitive landscape in the obesity market will change once the new drugs such as Novo Nordisk’s liraglutide, Vivus’s Qnexa, Arena Pharmaceutical’s Lorcaserin and Orexigen’s Contrave are launched successfully.
Metabolic Disorders Therapeutics Market, Global, Market Share of Top Manufacturers, 2008
Source: GBI Research
Note: Others Include players such as Pfizer, Bristol Myers Squibb, Kissei Pharmaceuticals, Teva Pharmaceuticals and generic drugs manufacturers
The Unmet Need and Growth Potential in the Metabolic Disorders Therapeutics Market is Driving Players to Adopt Licensing and Mergers and Acquisition Strategy
GBI Research indicates that the metabolic disorder therapeutics market has a moderately active mergers and acquisition (M&A) landscape. Only a few major pharmaceutical companies and medium players are looking for strategic partnerships with companies that have promising drugs either in the pipeline or in the market. During the period 2008-2009, a total of 35 M&A and licensing deals took place. Most of the M&A and licensing deals involved companies active in the diabetes market. The diabetes and obesity markets face unmet need regarding the efficacy and safety of the drugs available. The diabetes market has unmet need for drugs which are easier to administer and the obesity market requires drugs which do not have serious side effects. This unmet need and the growth potential are driving the deals activity in the industry. The major acquisition activity that took place in 2008-2009 was GlaxoSmithKline’s (GSK) acquisition of Sirtris Pharmaceuticals. The acquisition considerably added to the pipeline potential of GSK in the diabetes market. Licensing activities involving approved products such as Januvia and Galvus and phase III products such as Oral-lyn will impact the market. GBI Research suggests that the licensing and M&A activity will continue to be an important strategy for players to strengthen their market positions.
About GBI Research
GBI Research is a leading business information company providing global business information reports and services.
Our highly qualified team of Analysts, Researchers, and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyze and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.
More Endocrinology/Metabolics reports by GBI Research
Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement Therapy by GBI Research
Women’s Health Therapeutics Market to 2018 - Unmet Need for Safe and Effective Treatments due to Unfavorable Risk/Benefit Profile Associated with Hormone Replacement TherapySummaryGBI Research, ...
Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for Patients by GBI Research
Endocrinology Market to 2018 - Advanced Injection Devices for Growth Hormone and Somatostatin will Improve Ease of Use for PatientsSummaryGBI Research, the leading business intelligence ...
Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market Value by GBI Research
Metabolic Disorders Therapeutics Market to 2017 - Patent Expiry of Lipitor in 2011 will Negatively Impact Dyslipidemia Market ValueSummaryGBI Research, the leading business intelligence provider, ...
Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market by GBI ResearchSee all reports like this >>
Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the MarketSummaryGBI Research has released ...